- Payment follows dosing of the first patient in a Phase 3 trial of APP13007 for the treatment of inflammation and pain after cataract surgery
- APP13007 originated at Activus Pharma, a former subsidiary of Sosei Heptares now owned by Formosa
- Sosei Heptares remains eligible to receive undisclosed milestone payments and royalties based on the progression of Activus' pipeline at Formosa
PR Newswire
TOKYO and CAMBRIDGE, England, March 11, 2021